VRAX

Business Context and Reporting Period

Company: Virax Biolabs Group Ltd (VRAX)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended March 31, 2026
Business Overview: Virax Biolabs is a Cayman Islands-based holding company focused on immune response detection and T cell immune profiling. Its primary development program is ViraxImmune™, a T cell-based diagnostic platform targeting post-acute infection syndromes (PAIS) such as Long COVID and ME/CFS. The company also maintains an ImmuneSelect portfolio of research-use-only (RUO) products. The company has limited operating history and has incurred operating losses since inception.

Key Financial Metrics

Note: Share counts reflect retroactive adjustments for share consolidations (1-for-10 in Dec 2023 and 1-for-25 in June 2026).

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased to $12,423 in FY 2026 from $6,331 in FY 2025, driven by increased sales of RUO test kits. However, this represents a significant decline from FY 2024 ($156,419) as the company discontinued its historical ViraxClear and ViraxVet distribution lines.
• Expense Management: General and administrative expenses decreased by approximately 33% ($1.32 million) compared to FY 2025, primarily due to reduced personnel costs. Conversely, R&D expenses increased by 84% ($1.71 million) due to accelerated clinical studies and increased payroll for the ViraxImmune platform.
• Net Loss Reduction: Net loss improved to $5.03 million in FY 2026 from $6.07 million in FY 2025, aided by a significant income tax benefit of $900,240 (R&D tax credits) compared to $136,661 in the prior year.
• Liquidity Position: Cash balance increased by $2.21 million to $6.44 million, primarily funded by financing activities including a private placement offering (PIPE) and At-the-Market (ATM) sales.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: The filing explicitly states that the company's recurring losses and accumulated deficit raise substantial doubt about its ability to continue as a going concern. Continued operations depend on securing additional financing.
• Regulatory Pathway: The company is pursuing a U.S. Laboratory-Developed Test (LDT) pathway for ViraxImmune, followed by a potential IVD pathway. It completed a pre-submission meeting with the FDA in calendar year 2025. No regulatory approvals have been obtained to date.
• Share Consolidation: To regain compliance with Nasdaq listing standards (minimum bid price), the company executed a 1-for-25 share consolidation effective June 26, 2026. All historical share data in the filing has been retroactively adjusted.
• Intellectual Property Risk: The company discloses it does not own any patents, relying instead on trade secrets and copyrights, which may limit its ability to protect proprietary technology.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2026, due to control deficiencies in internal control over financial reporting.

Investor Verification Checklist

• Cash Runway: Verify if the current cash balance of $6.44 million is sufficient to fund the accelerated R&D program and operations for the next 12-18 months given the lack of significant revenue.
• Regulatory Milestones: Confirm the status of the FDA pre-submission meeting outcomes and the timeline for the LDT pathway, as commercialization is entirely dependent on this.
• Share Consolidation Impact: Review the impact of the 1-for-25 reverse split on shareholder liquidity and the company's ability to maintain the $1.00 minimum bid price on Nasdaq.
• Internal Control Deficiencies: Assess the specific nature of the ineffective internal controls and the remediation plan, as this poses a risk to financial reporting accuracy.
• Patent Strategy: Evaluate the long-term competitive risk of having no patent portfolio in the biotechnology sector.